Fesoterodine for the treatment of urinary incontinence and overactive bladder.
about
Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective studyBladder dysfunction in diabetes mellitus.Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.Update on the management of overactive bladder: patient considerations and adherenceUrinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral Ligation.
P2860
Fesoterodine for the treatment of urinary incontinence and overactive bladder.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Fesoterodine for the treatment of urinary incontinence and overactive bladder.
@en
Fesoterodine for the treatment of urinary incontinence and overactive bladder.
@nl
type
label
Fesoterodine for the treatment of urinary incontinence and overactive bladder.
@en
Fesoterodine for the treatment of urinary incontinence and overactive bladder.
@nl
prefLabel
Fesoterodine for the treatment of urinary incontinence and overactive bladder.
@en
Fesoterodine for the treatment of urinary incontinence and overactive bladder.
@nl
P2860
P356
P1476
Fesoterodine for the treatment of urinary incontinence and overactive bladder.
@en
P2093
Pamela Ellsworth
P2860
P304
P356
10.2147/TCRM.S6483
P577
2009-11-18T00:00:00Z